|
Neoplasia
Citations 441-450 of 4217 total displayed.
|
Past content
(since Jan 1997):
|
The TCL1 oncoprotein inhibits activation-induced cell death by impairing PKC and ERK pathways
- Gilles Despouy, Marjorie Joiner, Emilie Le Toriellec, Robert Weil, and Marc Henri Stern
Blood 2007; 110: 4406-4416.
[Abstract]
[Full text]
[PDF]
The Akt pathway regulates survival and homing in Waldenstrom macroglobulinemia
- Xavier Leleu, Xiaoying Jia, Judith Runnels, Hai T. Ngo, Anne-Sophie Moreau, Mena Farag, Joel A. Spencer, Costas M. Pitsillides, Evdoxia Hatjiharissi, Aldo Roccaro, Garrett O'Sullivan, Douglas W. McMillin, Daisy Moreno, Tanyel Kiziltepe, Ruben Carrasco, Steven P. Treon, Teru Hideshima, Kenneth C. Anderson, Charles P. Lin, and Irene M. Ghobrial
Blood 2007; 110: 4417-4426.
[Abstract]
[Full text]
[PDF]
An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells
- Monica L. Guzman, Randall M. Rossi, Sundar Neelakantan, Xiaojie Li, Cheryl A. Corbett, Duane C. Hassane, Michael W. Becker, John M. Bennett, Edmund Sullivan, Joshua L. Lachowicz, Andrew Vaughan, Christopher J. Sweeney, William Matthews, Martin Carroll, Jane L. Liesveld, Peter A. Crooks, and Craig T. Jordan
Blood 2007; 110: 4427-4435.
[Abstract]
[Full text]
[PDF]
Rapid and selective death of leukemia stem and progenitor cells induced by the compound 4-benzyl, 2-methyl, 1,2,4-thiadiazolidine, 3,5 dione (TDZD-8)
- Monica L. Guzman, Xiaojie Li, Cheryl A. Corbett, Randall M. Rossi, Timothy Bushnell, Jane L. Liesveld, Josée Hébert, Fay Young, and Craig T. Jordan
Blood 2007; 110: 4436-4444.
[Abstract]
[Full text]
[PDF]
A role for the MLL fusion partner ENL in transcriptional elongation and chromatin modification
- Dorothee Mueller, Christian Bach, Deniz Zeisig, Maria-Paz Garcia-Cuellar, Sara Monroe, Arun Sreekumar, Rong Zhou, Alexey Nesvizhskii, Arul Chinnaiyan, Jay L. Hess, and Robert K. Slany
Blood 2007; 110: 4445-4454.
[Abstract]
[Full text]
[PDF]
Genetic variation in 1253 immune and inflammation genes and risk of non-Hodgkin lymphoma
- James R. Cerhan, Stephen M. Ansell, Zachary S. Fredericksen, Neil E. Kay, Mark Liebow, Timothy G. Call, Ahmet Dogan, Julie M. Cunningham, Alice H. Wang, Wen Liu-Mares, William R. Macon, Diane Jelinek, Thomas E. Witzig, Thomas M. Habermann, and Susan L. Slager
Blood 2007; 110: 4455-4463.
[Abstract]
[Full text]
[PDF]
The new tumor-suppressor gene inhibitor of growth family member 4 (ING4) regulates the production of proangiogenic molecules by myeloma cells and suppresses hypoxia-inducible factor-1  (HIF-1) activity: involvement in myeloma-induced angiogenesis
- Simona Colla, Sara Tagliaferri, Francesca Morandi, Paolo Lunghi, Gaetano Donofrio, Davide Martorana, Cristina Mancini, Mirca Lazzaretti, Laura Mazzera, Lara Ravanetti, Sabrina Bonomini, Luca Ferrari, Claudia Miranda, Marco Ladetto, Tauro Maria Neri, Antonino Neri, Angela Greco, Marcellina Mangoni, Antonio Bonati, Vittorio Rizzoli, and Nicola Giuliani
Blood 2007; 110: 4464-4475.
[Abstract]
[Full text]
[PDF]
Uniform sensitivity of FLT3 activation loop mutants to the tyrosine kinase inhibitor midostaurin
- Elly V. Barry, Jennifer J. Clark, Jan Cools, Johannes Roesel, and D. Gary Gilliland
Blood 2007; 110: 4476-4479.
[Abstract]
[Full text]
[PDF]
Preemptive HMG-CoA reductase inhibition provides graft-versus-host disease protection by Th-2 polarization while sparing graft-versus-leukemia activity
- Robert Zeiser, Sawsan Youssef, Jeanette Baker, Neeraja Kambham, Lawrence Steinman, and Robert S. Negrin
Blood 2007; 110: 4588-4598.
[Abstract]
[Full text]
[PDF]
Hepatitis C virus infection and risk of posttransplantation lymphoproliferative disorder among solid organ transplant recipients
- Lindsay M. Morton, Ola Landgren, Nilanjan Chatterjee, David Castenson, Ruth Parsons, Robert N. Hoover, and Eric A. Engels
Blood 2007; 110: 4599-4605.
[Abstract]
[Full text]
[PDF]
|
|
